Cannabis for MS Spasticity: A Systematic Review With Critically Unreliable Pooled Estimates
This cannabis MS spasticity review examines nine trials with 2,544 patients but finds critically unreliable pooled estimates due to extreme heterogeneity. The meta-analysis reports numerically implausible effect sizes and suspected publication bias.…
Cannabis Does Not Consistently Change Sleep Architecture, Meta-Analysis Finds
A 2025 meta-analysis finds cannabis withdrawal sleep disruption is consistent, while cannabis does not reliably change sleep architecture. Polysomnographic evidence shows no clear benefit or harm on most sleep parameters. These findings highlight the…
Cannabinoid Clinical Trials for Mental & Substance Disorders
Cannabinoid clinical trials mental disorders reveal limited evidence supporting cannabinoids as primary treatments. Current data do not establish clear efficacy or safety profiles. Clinicians should interpret patient interest with caution until stronger…
The association between major depressive disorder and cannabis use disorder: A meta-analysis and meta-regression analysis.
This meta-analysis on major depressive disorder cannabis use meta-analysis reveals significant prevalence of co-occurring conditions. It highlights the importance of integrated screening and treatment. Understanding this relationship is crucial for…
Health-related quality of life in patients receiving medicinal cannabis: systematic review and meta-analysis of primary research findings 2015-2025.
This systematic review and meta-analysis examines health-related quality of life medicinal cannabis outcomes in patients with chronic conditions. The study standardizes outcome measurement across multiple timeframes. Findings support improved quality of…
Cannabinoids for Mental Health: Large Review Finds Mostly Low-Quality Evidence With Few Clear Benefits
The 2026 systematic review on cannabinoids for mental health reveals mostly low-quality evidence with few clear benefits. This comprehensive analysis highlights limited support for cannabinoids in treating mental disorders. More high-quality research is…
The efficacy and safety of cannabinoids for mental and substance use disorders
This review examines cannabinoids for mental substance use disorders evidence, focusing on their efficacy and safety. Mental health and substance use disorders are common reasons for cannabinoid use. The study highlights the need for careful clinical…
Research Digest: 40 Recent Cannabis Clinical Studies – March 20, 2026
This research digest cannabis clinical studies March 2026 compiles 40 recent peer-reviewed studies curated for clinical relevance and evidence quality. It highlights key findings from cannabis clinical research and evidence reviews. Stay informed with…
Comprehensive Review Reveals Cannabis Use Disorder Affects 10% of World’s 193 Million Cannabis Users
Cannabis use disorder epidemiology shows it affects about 10% of cannabis users worldwide. Risk increases with frequency of use and early initiation. Psychosocial treatments exist but no approved medications are available.
Medical Cannabis Not Effective as a Mental Health Treatment, Finds Meta Analysis
A recent meta-analysis evaluated medical cannabis mental health efficacy and found insufficient evidence supporting its use for psychiatric disorders. Clinicians should counsel patients on the limited benefits of medical cannabis for anxiety and…